Stockscreener 앱 받기
0.041
141.18%
0.024
전일 마감가:
$0.017
열려 있는:
$0.05
하루 거래량:
52,711
Relative Volume:
28.68
시가총액:
$N/A
수익:
-
순이익/손실:
$149.05M
주가수익비율:
0.0207
EPS:
1.9846
순현금흐름:
$-6.05M
1주 성능:
+141.18%
1개월 성능:
+141.18%
6개월 성능:
+141.18%
1년 성능:
-96.95%
1일 변동 폭
$0.041
$0.05
1주일 범위
$0.041
$0.05
52주 변동 폭
$0.017
$0.05
갈레라 테라 Stock (GRTX) Company Profile
Compare GRTX vs VRTX, REGN, ARGX, ALNY, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
GRTX
Galera Therapeutics Inc
|
0.041 | 0 | 0 | 149.05M | -6.05M | 1.9846 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
갈레라 테라 Stock (GRTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-08-10 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-10-19 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2021-10-19 | 다운그레이드 | BofA Securities | Buy → Underperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-12-16 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2020-12-07 | 개시 | H.C. Wainwright | Buy |
| 2019-12-02 | 개시 | BTIG Research | Buy |
| 2019-12-02 | 개시 | BofA/Merrill | Buy |
| 2019-12-02 | 개시 | Citigroup | Buy |
| 2019-12-02 | 개시 | Credit Suisse | Neutral |
모두보기
갈레라 테라 주식(GRTX)의 최신 뉴스
Galera Therapeutics schedules combined 2025 and 2026 annual meeting for May - Investing.com Australia
Galera Sets Deadlines for 2026 Combined Annual Meeting - TipRanks
Galera Therapeutics schedules combined 2025-2026 annual meeting for May 8, 2026; April 13 proposal deadline - TradingView
Galera Therapeutics (GRTX) sets 2026 meeting date and April 13 proposal deadline - Stock Titan
Galera Therapeutics 10-K: Revenue $0, EPS $0.64 on $149.0M Net Income - TradingView
Galera Therapeutics (GRTX) exits radiotherapy, bets on pan-NOS breast cancer drug - Stock Titan
Galera Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
GRTX (Galera Therapeutics) NonCurrent Deferred Revenue : $0.00 Mil (As of Sep. 2025) - GuruFocus
Galera Therapeutics Sells Dismutase Mimetics Portfolio to Biossil in $108.5 Million Deal - MSN
GRTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Galera Therapeutics Updates Preferred Stock Conversion Provisions - TipRanks
Galera Therapeutics (GRTX) grants board discretion on Series B conversion - Stock Titan
Galera Therapeutics Grants Retention Bonus to Key Officer - TipRanks
Doylestown’s Aprea Therapeutics Names Industry Veteran as Chief Medical Advisor - BUCKSCO.Today
Aprea Therapeutics, Inc. Appoints Eugene Kennedy as Chief Medical Advisor - marketscreener.com
Galera Therapeutics completes acquisition of Nova Pharmaceuticals - Intellectia AI
Malvern-based Galera Therapeutics Secures New Lease on Life with Acquirement Underway - MSN
Head to Head Analysis: Lite Strategy (NASDAQ:LITS) and Galera Therapeutics (NASDAQ:GRTX) - Defense World
GRTX (Galera Therapeutics) EV-to-OCF : 0.32 (As of Dec. 19, 2025) - GuruFocus
Chmn Sorensen Sells 70,000 ($1.4K) Of Galera Therapeutics Inc [GRTX] - TradingView
GRTX Form 4: CEO Sorensen reports 70,000-share stock sale - Stock Titan
Chmn Sorensen Files To Sell 70,000 Of Galera Therapeutics Inc [GRTX] - TradingView — Track All Markets
Galera Therapeutics, Inc. SEC 10-Q Report - TradingView
Galera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
[10-Q] Galera Therapeutics, Inc. Quarterly Earnings Report | GRTX SEC FilingForm 10-Q - Stock Titan
Deal Watch: GSK To Tap AN2’s Boron Chemistry Approach In Tuberculosis R&D - Citeline News & Insights
Aprea Therapeutics Reports Early Signs of Activity in APR-1051 Cancer Trial - MyChesCo
Canadian company purchases Galera Therapeutics’ dismutase mimetics portfolio - Pennsylvania Business Report -
Galera Therapeutics Sells Assets to Biossil Inc. - TipRanks
Biossil to acquire Galera’s dismutase mimetics portfolio for up to $105M - MSN
Galera Therapeutics Acquires Dismutase Mimetics Portfolio by Biossil For $105 Million - citybiz
Galera Therapeutics (GRTX) Sells Asset Portfolio to Biossil - GuruFocus
Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million - Yahoo Finance
Malvern firm selling drug portfolio in potential $105M deal after FDA setback - The Business Journals
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Oral Mucositis Market Size & Share | Industry Report, 2033 - Grand View Research
NanoCell Therapeutics Expands Scientific Advisory Board With Global Experts in Gene Therapy and Clinical Development - MyChesCo
Avasopasem manganese treatment for severe oral mucositis from chemoradiotherapy for locally advanced head and neck cancer: phase 3 randomized controlled trial (ROMAN) - The Lancet
Legend Biotech CorporationAmerican Depositary Shares (NQ: - FinancialContent
Galera Therapeutics Amends Royalty Agreement with Clarus - The Globe and Mail
Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight - Yahoo Finance
Windtree Therapeutics to Launch BNB Crypto Treasury Strategy in Groundbreaking $200 Million Deal - MyChesCo
Warrington’s Windtree Therapeutics Acquires Waste Management Company - BUCKSCO.Today
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - GlobeNewswire
Oral Mucositis Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors - Business Wire
Galera Therapeutics Inc. (GRTX) reports earnings - qz.com
Chemotherapy Oral Mucositis Market Trends 2025-2035 - Future Market Insights
Festive biotech M&A spree sees Poolbeg combine with Hookipa, while Vincerx braces for layoffs - Fierce Biotech
Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals
Radiation Induced Esophagitis Market Set to Grow Substantially Through 2032, DelveInsight Projects | Galera Therapeutics - The Globe and Mail
갈레라 테라 (GRTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.49%
1.47%
자본화:
|
볼륨(24시간):